Key Publications
Through collaboration with leading researchers worldwide, we apply scientific rigor and cutting-edge innovation to advance precision oncology.
Key Publications by Topic:
Cancer Screening
- Expert Review of Pharmacoeconomics & Outcomes Research: Cost-effectiveness of blood-based colorectal cancer screening – a simulation model incorporating real-world longitudinal adherence
- The American Journal of Gastroenterology: Real-World Adherence to Repeat Testing for Stool-Based Non-Invasive Colorectal Cancer Screening Tests Among Individuals With Average Risk
- Journal of Medical Economics: Population health outcomes of blood-based screening for colorectal cancer in comparison to current screening modalities: insights from a discrete-event simulation model incorporating longitudinal adherence
- New England Journal of Medicine: A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening
- Gut: Blood-based colorectal cancer screening in an integrated health system: a randomised trial of patient adherence
- PLOS One: “I was screaming hallelujah”: Patient and provider perceptions of blood-based testing for colorectal cancer screening
- Annals of Oncology: High accuracy of a blood ctDNA-based multimodal test to detect colorectal cancer
- Digestive Disease Week 2023: Clinical Validation of a Cell-Free DNA Blood-Based Test for Colorectal Cancer Screening in an Average Risk Population
- Journal of Clinical Oncology: Validation of a multi-modal blood-based test for the detection of colorectal cancer with sub single molecule sensitivity
- Journal of Clinical Oncology: Prospective study of a multi-modal blood-based test for colorectal cancer screening
- Journal of Clinical Oncology: Development of a highly sensitive multicancer, targeted, cell-free DNA epigenomic assay for integrated screening of lung and colorectal cancer
- The American Journal of Gastroenterology: Multimodal circulating tumor DNA blood-based colorectal cancer screening test demonstrates clinically meaningful sensitivity across multiple clinical parameters
- Journal of Clinical Oncology: Multimodal circulating tumor DNA (ctDNA) colorectal neoplasia detection assay for asymptomatic and early-stage colorectal cancer
- American Association for Cancer Research: Integrated genomic and epigenomic cell-free DNA (cfDNA) analysis for the detection of early-stage colorectal cancer (CRC)
- American Association for Cancer Research: Understanding patient-reported barriers to colorectal cancer screening: A literature review
- American Association for Cancer Research: Combined genomic and epigenomic assessment of cell-free circulating tumor DNA (ctDNA) improves assay sensitivity in early-stage colorectal cancer (CRC)
Early-Stage Cancer Minimal Residual Disease Detection
- Clinical Cancer Research: Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease Assay
- A Cancer Journal for Clinicians: Locally advanced mismatch repair-deficient gastroesophageal junction cancer: Diagnosis, treatment modifications, and monitoring
- JCO Precision Oncology: Tumor-Informed Versus Plasma-Only Liquid Biopsy Assay in a Patient With Multiple Primary Malignancies
- Cancer Research: Multiomic, Plasma-Only Circulating Tumor DNA (ctDNA) Assay Identifies Breast Cancer Patients With Minimal Residual Disease (MRD) and Predicts Distant Recurrence
- Clinical Cancer Research: Minimal Residual Disease Detection using a Plasma-Only Circulating Tumor DNA Assay in Colorectal Cancer Patients
- Clinical Cancer Research: Clinical impact of pre-surgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: a biomarker study from the GEMCAD1402 Trial
Advanced Cancer Treatment Selection
- The Journal of Molecular Diagnostics: Analytical and Clinical Validation of the Plasma-Based Guardant360 CDx Test for Assessing HER2 (ERBB2) Mutation Status in Patients with Non–Small-Cell Lung Cancer for Treatment with Trastuzumab Deruxtecan in DESTINY-Lung01/02
- NPJ Breast Cancer: Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer
- Cancer Research Communications: Impact of tumor-intrinsic molecular features on survival and acquired tyrosine kinase inhibitor resistance in ALK-positive NSCLC
- Journal of the National Comprehensive Cancer Network: Associations Among Optimal Lung Cancer Treatment, Clinical Outcomes, and Health Care Utilization in Patients Who Underwent Comprehensive Genomic Profiling
- Journal of Clinical Oncology: HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
- JCO Precision Oncology: Association between availability of molecular genotyping results and overall survival in patients with advanced NSCLC
- Clinical Lung Cancer: Liquid Biopsy versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC)
- JCO Precision Oncology: Impact of Simultaneous Circulating Tumor DNA and Tissue Genotyping in the Workup of Stage IV Lung Adenocarcinoma on Quality of Care in an Academic Community Medical Center
- JCO Precision Oncology: A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression
- Cancer Discovery: Comutations and KRAS G12C inhibitor efficacy in advanced NSCLC
- JCO Precision Oncology: Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy
- Clinical Cancer Research: The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2 mutated, non-amplified metastatic breast cancer
- JTO Clinical and Research Reports: Plasma genotyping at the time of diagnostic tissue biopsy decreases time to treatment in patients with advanced NSCLC – results from a prospective pilot study
- Frontiers in Oncology: Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA
- Journal of Clinical Oncology: Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
- ESMO Open: Clinical Utility of Comprehensive Circulating Tumor DNA Genotyping Compared to Standard of Care Tissue Testing in Patients with Newly Diagnosed Metastatic Colorectal Cancer
- Clinical Lung Cancer: Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer
- European Journal of Cancer: Up-Front Cell-Free DNA Next Generation Sequencing Improves Target Identification in UK First Line Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
- British Journal of Cancer: Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma
- Clinical Cancer Research: Circulating tumor DNA (ctDNA) kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403)
- JCO Precision Oncology: Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary
- JCO Precision Oncology: Biomarker discovery and outcomes for comprehensive cell-free circulating tumor DNA versus standard-of-care tissue testing in advanced non-small-cell lung cancer
- Clinical Cancer Research: Tumor tissue- versus plasma-based genotyping for selection of matched therapy and impact on clinical outcomes in patients with metastatic breast cancer
- Nature Medicine: Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial
- Lancet Oncology: Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
- Journal of ImmunoTherapy of Cancer: Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
- Clinical Cancer Research: Routine Plasma-based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations Among Patients with Advanced Solid Tumors
- JAMA Oncology: Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-Line Treament of Metastatic NSCLC. The MYSTIC Phase 3 Randomized Clinical Trial
- Nature Medicine: Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
- Cancer: Spectrum of Driver Mutations and Clinical Impact of Circulating Tumor DNA Analysis in Non–Small Cell Lung Cancer: Analysis of Over 8000 Cases
- Clinical Cancer Research: Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel
- Clinical Cancer Research: Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients With Newly Diagnosed Metastatic Non-Small Cell Lung Cancer
- JCO Precision Oncology: Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer
- New England Journal of Medicine: Tepotinib in Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
- JCO Precision Oncology: Use of Low-Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non–Small-Cell Lung Cancer: A Multicenter Case Series
- Clinical Cancer Research: The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients
- Journal of Thoracic Oncology: Cell-Free DNA (cfDNA) Testing in Lung Adenocarcinoma (LUAC) Patients: Spanish Lung Liquid Versus Invasive Biopsy Program
- Clinical Cancer Research: Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies
- Clinical Cancer Research: Cell-Free DNA and Circulating Tumor Cells:Comprehensive Liquid Biopsy Analysis inAdvanced Breast Cancer
- Cancer Discovery: Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
- Clinical Lung Cancer: Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities
- Clinical Cancer Research: Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
- Clinical Cancer Research: Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung CancerPatients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
- Oncotarget: MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon
- Breast Cancer Res Treat: Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients
- Oncotarget: Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients
- PLOS One: Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
Advanced Cancer Treatment Response
- The New England Journal of Medicine: First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer
- Clinical Cancer Research: ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
- Communications Medicine: Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers
- Clinical Cancer Research: First-in-Human Study of the Ataxia Telangiectasia and Rad3-related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors
- Clinical Cancer Research: A Phase I/II Study of GSK525762 Combined With Fulvestrant in Patients With Hormone Receptor-Positive/HER2-Negative (HR+/HER2−) Advanced or Metastatic Breast Cancer
- Cancer Cell: BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
- Journal of Thoracic Oncology: Early ctDNA dynamics and efficacy of lorlatinib in patients with treatment-naïve, advanced, ALK-positive non-small cell lung cancer
- JCO Precision Oncology: Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy
- NPJ Breast Cancer: Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
- Journal of Clinical Oncology: Dynamic monitoring of circulating tumor DNA next-generation gene sequencing as a predictive biomarker of response and progression-free survival after pembrolizumab monotherapy in patients with advanced NSCLC
- Cancer Discovery: Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
- Journal of Clinical Oncology: Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC)